Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Nice touches abound
Sitagliptin is the first DPP-IV inhibitor approved by Food and Drug Administration (FDA) for the treatment of type 2 diabetes, and a large amount of preclinical and clinical data, as well as post-marketing monitoring data, demonstrate that it is an effective and safe DPP-IV inhibitor
148 P-gp substrates are structurally diverse, including paclitaxel, doxorubicin, vincristine, imatinib, and olaparib
Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies
De Feo CJ, Aller SG, Siluvai GS, Blackburn NJ, Unger VM
US$ 23.07
US$ 21.89
US$ 22.60
US$ 28.65
